Novo Nordisk Shares Quiet; Co. Announces Results From 3 Phase 2 Trials For Insulin Icodec, Primary Endpoint Showed Insulin Icodec With Loading Dose Showed Significantly Greater Time In Range vs Insulin Glargine U100